Cynata Therapeutics Limited (FRA:51S)
Germany
· Delayed Price · Currency is EUR 0.137
+0.010 (7.87%)
At close: Dec 4, 2025
Cynata Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Other Revenue | 1.89 | 2.32 | 1.65 | 7.77 | 1.55 | Upgrade
|
| Revenue | 1.89 | 2.32 | 1.65 | 7.77 | 1.55 | Upgrade
|
| Revenue Growth (YoY) | -18.59% | 39.98% | -78.71% | 402.60% | -77.95% | Upgrade
|
| Gross Profit | 1.89 | 2.32 | 1.65 | 7.77 | 1.55 | Upgrade
|
| Selling, General & Admin | 2.07 | 1.93 | 1.65 | 1.92 | 1.76 | Upgrade
|
| Research & Development | 7.4 | 8.68 | 12.39 | 8.82 | 3.78 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | Upgrade
|
| Other Operating Expenses | 1.49 | 1.42 | 1.89 | 1.78 | 1.73 | Upgrade
|
| Operating Expenses | 11.5 | 12.55 | 16.54 | 13.84 | 9.08 | Upgrade
|
| Operating Income | -9.61 | -10.23 | -14.89 | -6.07 | -7.53 | Upgrade
|
| Interest & Investment Income | 0.23 | 0.42 | 0.35 | 0.06 | 0.09 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | 0.07 | 0.26 | 0.56 | -0.3 | Upgrade
|
| EBT Excluding Unusual Items | -9.39 | -9.74 | -14.28 | -5.45 | -7.74 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.05 | Upgrade
|
| Pretax Income | -9.39 | -9.74 | -14.28 | -5.45 | -7.69 | Upgrade
|
| Net Income | -9.39 | -9.74 | -14.28 | -5.45 | -7.69 | Upgrade
|
| Net Income to Common | -9.39 | -9.74 | -14.28 | -5.45 | -7.69 | Upgrade
|
| Shares Outstanding (Basic) | 205 | 180 | 145 | 143 | 130 | Upgrade
|
| Shares Outstanding (Diluted) | 205 | 180 | 145 | 143 | 130 | Upgrade
|
| Shares Change (YoY) | 14.09% | 23.80% | 1.27% | 9.85% | 24.80% | Upgrade
|
| EPS (Basic) | -0.05 | -0.05 | -0.10 | -0.04 | -0.06 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.05 | -0.10 | -0.04 | -0.06 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -509.82% | -441.78% | -899.97% | -78.09% | -487.33% | Upgrade
|
| Profit Margin | -498.14% | -420.82% | -863.05% | -70.08% | -497.38% | Upgrade
|
| EBITDA | -9.33 | -9.95 | -14.61 | -5.79 | -7.25 | Upgrade
|
| EBITDA Margin | - | - | - | -74.48% | - | Upgrade
|
| D&A For EBITDA | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | Upgrade
|
| EBIT | -9.61 | -10.23 | -14.89 | -6.07 | -7.53 | Upgrade
|
| EBIT Margin | - | - | - | -78.09% | - | Upgrade
|
| Revenue as Reported | 2.11 | 2.73 | 2.01 | 7.84 | 1.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.